Pioneering click chemistry in humans

Read more about our work


Shasqi would like to congratulate our advisor Carolyn Bertozzi as well as Dr. Meldal and Dr. Sharpless on the 2022 Nobel Prize in Chemistry for the development of click chemistry and bioorthogonal chemistry.

About Shasqi

Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ (Click Activated Protodrugs Against Cancer) platform. The technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two ‘click’, a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds. We have already proven that our platform works in humans, which opens up an array of future possibilities for click-chemistry based therapies.

Overview of the CAPAC platform development

  • 2001

    The term click chemistry is coined by Kolb, Finn and Sharpless: a highly selective set of chemical reactions that can occur even in a glass of water.

    Read More
  • 2004

    Prescher, Dube, and Bertozzi report the use of click chemistry to modify cells in living animals.

    Read More
  • 2008

    Blackman, Royzen, and Fox pioneer the tetrazine ligation, an exceptionally powerful and efficient type of click chemistry.

    Read More
  • 2014

    Shasqi’s founder presents the foundational concepts of the Click Activated Protodrugs Against Cancer (CAPAC) Platform and shows the concept works in mice using the tetrazine ligation.

    Read More
  • 2016

    Shasqi shows that a cancer drug improved with the CAPAC Platform can lead to fewer side effects and better efficacy against tumors in mice.

    Read More
  • 2019

    Shasqi Announces Series A Financing.

    Read More
  • 2020

    FDA and Australian Ethics Committee provide permission to proceed with first in human clinical study.

    Read More
  • 2020

    Shasqi presents anti-tumor responses for SQ3370, CAPAC’s lead candidate, in preclinical cancer model. (AACR)

    Read More
  • 2020

    The first patient dosed with Shasqi's SQ3370. First ever use of click chemistry in humans.

    Read More
  • 2022

    Shasqi's SQ3370 clinical trial advances to Phase 2

    Read More
  • 2022

    2022 Nobel Prize in Chemistry is awarded to Click Chemistry and Bioorthogonal Chemistry

    Read More